Moreover, in the last 10 years, the role of the AHR as a therapeutic target in cancers has emerged in particular through the involvement of agonists and inhibitors in breast cancer, hepatocellular carcinoma, and melanoma [20,27,28,29,30,31,32,33]. This evidence concerns the gene AHR and hepatocellular carcinoma.